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OBJECTIVES We examined whether the adenosine triphosphate (ATP)-sensitive potassium (KATP)
channel openers (KCOs) block myocardial hypertrophy and whether the 70-kDa S6 kinase
(p70S6K) or extracellular signal-regulated kinase (ERK)-dependent pathway is involved.
BACKGROUND Long-term inhibition of nitric oxide (NO) synthesis induces cardiac hypertrophy indepen-
dent of blood pressure, by increasing protein synthesis in vivo. The KCOs attenuate calcium
overload and confer cardioprotection against ischemic stress, thereby preventing myocardial
remodeling.
METHODS Twelve Wistar-Kyoto rat groups underwent eight weeks of the drug treatment in combina-
tion with the NO synthase inhibitor N-nitro-L-arginine methyl ester (L-NAME), the
inactive isomer D-nitro-L-arginine methyl ester, KCOs (nicorandil, 3 and 10 mg/kg per day,
or JTV-506, 0.3 mg/kg per day), or the KATP channel blocker glibenclamide. The L-NAME
was also used with hydralazine, the p70S6K inhibitor rapamycin, or the mitogen-activated
protein kinase inhibitor PD98059. Finally, the left ventricular weight (LVW) to body weight
(BW) ratio was quantified, followed by histologic examination and kinase assay.
RESULTS The L-NAME increased blood pressure and LVW/BW, as compared with the control agent.
The KCOs and hydralazine equally cancelled the increase in blood pressure, whereas only
KCOs blocked the increase in LVW/BW and myocardial hypertrophy induced by L-NAME.
The L-NAME group showed both p70S6K and ERK activation in the myocardium (2.3-fold
and 2.0-fold increases, respectively), as compared with the control group, which was not
reversed by hydralazine. Selective inhibition of either p70S6K or ERK blocked myocardial
hypertrophy. The KCOs prevented the increase in activity only of p70S6K. Glibenclamide
reversed the effect of nicorandil in the presence of L-NAME.
CONCLUSIONS The KCOs modulate p70S6K, not ERK, to attenuate myocardial hypertrophy induced by
long-term inhibition of NO synthesis in vivo. (J Am Coll Cardiol 2002;40:991–7) © 2002
by the American College of Cardiology Foundation
Recently, angiotensin II, the key product of the renin-
angiotensin system, has been established as one of the
critical factors for myocardial hypertrophy (1,2) and fibrosis
(3), as well as other stimuli (4–6), such as norepinephrine,
phenylephrine, endothelin-1, and peptide growth factors.
These histologic changes are accepted to be the main
features of cardiac “remodeling,” as the result of many
cardiovascular diseases (7,8). Recent studies have proposed
that either extracellular signal-regulated kinase (ERK) (9–
11) or 70-kDa S6 kinase (p70S6K) (9,12,13), which phos-
phorylate the 40S ribosomal protein S6 that regulates
initiation of messenger ribonucleic acid translation (14,15),
as well as 90-kDa ribosomal S6 kinase (6,11), is the key
mediator of protein synthesis for hypertrophic changes
induced by angiotensin II. Activation of p70S6K is reported
to be involved in cardiac hypertrophy (13) and in the growth
and proliferation of endothelial cells (16), smooth muscle
cells (12), and fibroblasts (17).
In contrast, the adenosine triphosphate (ATP)-sensitive
potassium (KATP) channels, located on the sarcolemma (18)
and the inner membrane of the mitochondria (19) of
cardiomyocytes, are involved in the cardioprotection against
ischemia and reperfusion injuries (20,21). The opening of
mitochondrial KATP channels is reported to alter the redox
state of cardiomyocytes (22) and prevent mitochondrial
Ca2 overload (23), whereas the opening of sarcolemmal
KATP channels modulates cardiac Na
/K-ATPase activity
(24), shortens the action potential duration (25), and pre-
vents intracellular Ca2 overload (26). Because Ca2 acti-
vates protein kinase C (PKC) (27), which is reported to
elicit cardiac hypertrophic changes through the activation of
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ERK (28) or calmodulin-dependent protein kinases (29),
the KATP channel openers (KCOs) could potently inhibit
the hypertrophic changes induced by angiotensin II, possi-
bly by preventing Ca2overload. However, there has been
no study to test the effects of KCOs on cardiac hypertrophy.
To test this idea, we used the in vivo Wistar-Kyoto rat
model with long-term inhibition of nitric oxide (NO)
synthesis by N-nitro-L-arginine methyl ester (L-NAME).
Nitric oxide is known to mediate vasodilation, inhibit
platelet aggregation and prevent leukocyte adhesion to
endothelial cells (30). However, the main features of this
model on the cardiovascular system are reported to be
myocardial remodeling (hypertrophy and fibrosis), coronary
remodeling (medial thickening and perivascular fibrosis)
and hypertension, mediated through the renin-angiotensin
system (9,31,32). We evaluated: 1) the myocardial structural
changes; 2) the tissue p70S6K and ERK activity; and 3) the
effects of KCOs (nicorandil [33] and JTV-506 [34]) on each
variable.
METHODS
All procedures were performed in accordance with the
Guide for the Care and Use of Laboratory Animals (National
Institutes of Health [NIH] publication no. 85-23, revised
1985).
The S6 peptide (RRRLSSLRA, no. 12-124) was ob-
tained from Upstate Biotechnology (Charlottesville, Virgin-
ia). Protein G/protein A–coupled beads were from Onco-
gene Sciences (Cambridge, Massachusetts). Nicorandil was
obtained from Chugai Pharmaceuticals (Tokyo, Japan).
JTV-506 was obtained from Japan Tobacco (Tokyo, Japan).
The other drugs were from Sigma (St. Louis, Missouri).
Instrumentation. Eighty eight-week-old male Wistar-
Kyoto rats were randomly classified into 12 groups. The
control group received no treatment. The L-NAME group
received 1 g/l of L-NAME in drinking water. The D-nitro-
L-arginine methyl ester (D-NAME, the inactive isomer of
L-NAME) group received 1 g/l of D-NAME in drinking
water. The L-NAME  hydralazine group received both
L-NAME and hydralazine (120 mg/l in drinking water).
The L-NAME  JTV group, L-NAME  Ncr3 group,
L-NAME  Ncr10 group, L-NAME  Rap group, and
L-NAME  PD group received JTV-506 (0.3 mg/kg per
day), nicorandil (3 or 10 mg/kg per day), nicorandil (10
mg/kg per day), rapamycin (a potent p70S6K inhibitor; 0.5
mg/kg per day), and PD98059 (a potent ERK kinase
inhibitor; 5 mg/kg per day), respectively (orally by ravage),
in addition to L-NAME (1 g/l in drinking water). In the
Glib group, L-NAME  Glib group, and L-NAME 
Ncr10  Glib group, the KATP channel blocker gliben-
clamide (5 mg/kg per day; orally by gavage) was given in
combination with both L-NAME and nicorandil (10 mg/kg
per day). We decided on the doses of hydralazine, JTV-506,
nicorandil, rapamycin, PD98059, and glibenclamide, ac-
cording to our preliminary experiments (data not shown)
Figure 1. Time-course changes in systolic blood pressure. See text for details. Glib  glibenclamide; Hyd  hydralazine; JTV0.3  JTV-506 at 0.3 mg/kg
per day; Ncr3 and Ncr10 nicorandil at 3 and 10 mg/kg per day, respectively; PD  PD98059; Rap  rapamycin. **p  0.01 vs. control group.
Abbreviations and Acronyms
ANOVA  analysis of variance
ATP  adenosine triphosphate
BW  body weight
D-NAME  D-nitro-L-arginine methyl ester
ERK  extracellular signal-regulated kinase
KATP  adenosine triphosphate-sensitive potassium
KCO  adenosine triphosphate-sensitive potassium
channel opener
L-NAME  N-nitro-L-arginine methyl ester
LVW  left ventricular weight
NO  nitric oxide
p70S6K  70-kDa S6 kinase
PKC  protein kinase C
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and previous report (9). Rats from all groups were housed in
a viral antigen-free facility and were fed with normal rat
chow for eight weeks. Both systolic blood pressure and heart
rate were measured by the tail-cuff method. After eight
weeks of treatment, all rats were anesthetized with an
intraperitoneal injection of thiopentobarbital and then sac-
rificed by exsanguination.
Histologic examination. Excised hearts were weighed, cut
and carefully scanned, as described previously (9,35). The
morphometry of left ventricular myocytes was assessed, and
the cross-sectional area was measured in cardiomyocytes,
according to a previous report (31).
Assay for p70S6K and ERK activity. The specific activity
of p70S6K was determined by 32P incorporation into the S6
peptide in the immune complex, as described (36–38). The
specific activity of ERK was determined, as described
previously (39). The experiments were performed twice for
each sample.
Statistical analysis. Data are expressed as the mean value
 SEM. Paired data were compared by the Student t test.
Comparisons of p70S6K activity, ERK activity, hemody-
namic variables (e.g., systemic blood pressure, heart rate),
body weight (BW), left ventricular weight (LVW) and
cardiomyocyte cross-sectional area were performed by one-
way analysis of variance (ANOVA), followed by the Bon-
ferroni multiple comparisons t test. A comparison of time-
course changes in systemic blood pressure was performed by
two-way repeated measures ANOVA, followed by the
multiple comparisons tests. A p value of 0.05 was consid-
ered statistically significant.
RESULTS
Arterial pressure, heart rate, and BW. Before treatment,
systemic blood pressure was comparable among the 12
groups studied. After eight weeks of treatment, systemic
blood pressure was comparable in each group, except in the
L-NAME, L-NAMENcr3, L-NAME Rap, L-NAME
 PD, and L-NAME  Glib groups, which had higher
levels (p  0.01) than those in the control group (Fig. 1).
The increase in blood pressure in this model was reversed by
a dose as high as 10 mg/kg per day of nicorandil or
hydralazine. The heart rate was comparable among the 12
groups studied and did not change significantly throughout
this study. Body weight increased significantly in all groups,
although the L-NAME, L-NAME  JTV, L-NAME 
Glib, and L-NAME  Ncr10  Glib groups had a lower
BW than that of the control group (Table 1).
Myocardial hypertrophy and LVW/BW ratio. After
eight weeks of treatment, the L-NAME, L-NAME  Hyd,
L-NAME  Ncr3, and L-NAME  Glib groups had a
significantly higher LVW than that of the control group
(Table 1).
However, a significant increase (p  0.01) in the
LVW/BW ratio was observed in the L-NAME, L-NAME
 Hyd, L-NAME  Glib, and L-NAME  Ncr10  Glib
Table 1. Changes in Body Weight and Left Ventricular Weight
in Each Group
n
Body Weight (g)
Baseline 4 Weeks 8 Weeks
Control 12 294  4 352  6* 392  10*
L-NAME 12 292  7 326  9†‡ 322  13‡§
D-NAME 8 298  3 365  6* 399  9*
L-NAME  Hyd 8 302  4 350  9* 379  8*
L-NAME  JTV0.3 8 292  3 345  8* 348  15*†
L-NAME  Ncr3 8 299  6 349  9* 372  11*
L-NAME  Ncr10 8 294  7 336  8* 365  7*
L-NAME  Rap 8 297  8 329  4‡ 360  10*
L-NAME  PD 6 288  5 342  5* 368  7*
Glib 8 289  4 344  4* 380  4*
L-NAME  Glib 8 290  8 336  9* 333  6*†
L-NAME  Ncr10  Glib 8 288  6 328  6†‡ 338  7*†
n
LV Weight
(mg)
8 Weeks
Control 12 812  16
L-NAME 12 939  27†
D-NAME 8 819  18
L-NAME  Hyd 8 1,079  37§
L-NAME  JTV0.3 8 768  14
L-NAME  Ncr3 8 959  19†
L-NAME  Ncr10 8 826  20
L-NAME  Rap 8 759  22
L-NAME  PD 6 909  44
Glib 8 784  19
L-NAME  Glib 8 942  35†
L-NAME  Ncr10  Glib 8 909  25
*p 0.01 vs. baseline. †p 0.05 vs. control group. ‡ p 0.05 vs. baseline. §p 0.01
vs. control group. Data are presented as the mean value  SEM.
D-NAME and L-NAME  D- and N-nitro-L-arginine. methyl ester, respec-
tively; Glib  glibenclamide; Hyd  hydralazine; JTV0.3  JTV-506 at 0.3 mg/kg
per day; Ncr3 and Ncr10  nicorandil at 3 and 10 mg/kg per day, respectively; PD 
PD98059; Rap  rapamycin.
Figure 2. The left ventricular (LV) weight /body weight ratios. *p  0.05
and **p  0.01 vs. control group. †p  0.05 and ††p  0.01 vs. L-NAME
group. Abbreviations as in Figure 1.
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groups, as compared with the control group (Fig. 2). Either
a higher dose of nicorandil, JTV-506, rapamycin or
PD98059, but neither a lower dose of nicorandil nor
hydralazine, prevented the increase in LVW/BW induced
by L-NAME (Fig. 2). The LVW/BW ratio in the
L-NAME  Ncr10  Glib group was significantly higher
than that in the L-NAME  Ncr10 group.
Representative histologic findings of the cross-sectional
areas of cardiomyocytes are shown in Figure 3A. The
cross-sectional areas of cardiomyocytes in the L-NAME
group were significantly (p 0.01) greater than those of the
control group (Fig. 3B). Higher and lower doses of
nicorandil, JTV-506, rapamycin or PD98059, but not
hydralazine, prevented the increase in the cross-sectional
areas of cardiomyocytes induced by L-NAME (Fig. 3B).
As seen in LVW/BW, the cross-sectional area of cardi-
omyocytes in the L-NAME  Ncr10  Glib group was
significantly higher than that in the L-NAME  Ncr10
group.
Activity of p70S6K and ERK in cardiac tissue. The
activity of p70S6K and ERK in cardiac tissue in the
L-NAME group was higher (p  0.01) than that in the
Figure 3. Representative histologic findings of myocytes (A) and myocyte cross-sectional areas (B). *p  0.05 and **p  0.01 vs. control group. †p  0.05,
††p  0.01 vs. L-NAME group. 1  control group; 2  L-NAME treatment; 3  D-NAME treatment; 4  L-NAME  Hyd treatment; 5  L-NAME
 JTV treatment; 6 L-NAMENcr3 treatment; 7 L-NAMENcr10 treatment; 8 L-NAME Rap treatment; 9 L-NAME PD treatment;
10  Glib treatment; 11  L-NAME  Glib treatment; and 12  L-NAME  Ncr10  Glib treatment. Abbreviations as in Figure 1.
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control group. Nicorandil, JTV-506, or rapamycin, but not
hydralazine nor PD98059, prevented the increase in
p70S6K activity induced by L-NAME (Fig. 4A). Only
PD98059 prevented the increase in ERK activity induced by
L-NAME (Fig. 4B).
DISCUSSION
We have demonstrated that: 1) the myocardial hypertrophy
induced by long-term inhibition of NO synthesis with
L-NAME is reduced by KCOs in a dose-dependent man-
ner, but not by hydralazine; 2) the KATP channel blocker
glibenclamide abolished this hypertrophy-reducing effect of
KCOs, whereas glibenclamide, per se, did not influence the
untreated heart; and 3) p70S6K activity in the myocardium
increases in rats treated with L-NAME, which was reduced
by either KCOs or rapamycin, but not by either hydralazine
or PD98059. Here we have shown for the first time, to the
best of our knowledge, that KCOs potentially prevent
myocardial structural changes induced by long-term inhibi-
tion of NO synthesis, through regulating p70S6K activity,
which is apart from ERK in vivo.
Features of myocardial hypertrophy induced by inhibi-
tion of NO synthesis. Long-term treatment with
L-NAME inhibits NO synthesis (40) and induces arterial
hypertension, cardiac hypertrophy, and remodeling (31).
However, these structural changes in the heart are indepen-
dent of arterial hypertension, as revealed by the data using
hydralazine. Furthermore, we have reported that reduced
plasma NO levels are linearly correlated with the severity of
hypertension in patients with essential hypertension (41),
suggesting that this model may represent the cardiac hyper-
trophy associated with clinical essential hypertension in
vivo. A variety of previous reports have proposed there are
several possible mechanisms by which the inhibition of NO
synthesis induces myocardial structural changes: 1) increases
in plasma renin activity (42) and local angiotensin-
converting enzyme activity (31) and upregulation of angio-
tensin II receptors (43), which increase the effect of angio-
tensin II; 2) expression of plasminogen activator inhibitor-1
(44) or the fetal skeletal alpha-actin isoform (42); and 3)
synthesis of growth factors in the endothelium (45,46).
We have previously demonstrated (47) that inhibition of
NO synthesis leads to PKC activation through a cyclic
guanosine monophosphate-independent mechanism,
which is also reported to be involved in the pathway of
angiotensin II-induced cardiac hypertrophy (11,28).
However, other reports have revealed that NO modifies
the vascular structure by directly modulating the growth
of vascular smooth muscle cells (48). Taken together, it is
likely that activation of the local or, in part, systemic
renin-angiotensin system and the associated increased
release of growth factors may contribute to cardiovascular
hypertrophy in both a PKC-dependent and -independent
fashion in this model.
Differential regulation of myocardial remodeling by
p70S6K and ERK. In the present study, either rapamycin
or PD98059 independently blocked or attenuated myocar-
dial remodeling. Furthermore, the KCOs prevented the
increase in activity only of p70S6K and attenuated cardiac
hypertrophy in a dose-dependent manner, which was re-
versed by the potent KATP channel blocker glibenclamide.
Taken together, it is suggested that opening of the KATP
channel potentially prevents myocardial structural changes
in the present in vivo model by regulating p70S6K, apart
from ERK. Accordingly, we have reported that inhibition of
NO synthesis in the same model induces cardiac remodel-
ing, along with activation of both p70S6K and ERK (9),
and modulation by angiotensin-converting enzyme inhibi-
tors or angiotensin II type 1 receptor blockers can equally
attenuate these changes by alternatively inhibiting p70S6K
and ERK (9). Other reports mention that these two
Figure 4. Activity of P70S6K (A) and ERK (B) in myocardial tissue. See
text for details. **p  0.01 vs. control group. †p  0.05 and ††p  0.01 vs.
L-NAME group. Abbreviations as in Figure 1.
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signaling pathways are independently involved in cardiac
hypertrophy (49). These data sufficiently support our
present results. p70S6K is reported to be activated by the
cytokines and hormonal and growth factors through
phosphoinositide-3 kinase activation (50), and it phosphor-
ylates S6. Furthermore, p70S6K is known to phosphorylate
a transcriptional factor—the cyclic adenosine monophos-
phate response-element modulator (51). Thus, p70S6K
might be important in transcriptional, as well as transla-
tional, regulation for protein synthesis.
Clinical implications. The KCOs have already been rec-
ognized as vasodilators (33,34) or potent agents for cardio-
protection against ischemic injury (20,21). We have shown
here for the first time, to the best of our knowledge, the
potency of KCOs in attenuating myocardial structural
changes, as well as the suggestive effecting point, p70S6K,
as another target to prevent myocardial remodeling. Because
it is hard to reverse cardiac remodeling completely by
various kinds of medications in clinical conditions, this
study proclaims the good clinical outcome of therapy with
KCOs against cardiac remodeling, especially in those with
clinical hypertension. Further studies are needed to adapt
and establish these strategies safely and effectively in clinical
cardiology.
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